Crystalline Glucosamine Sulfate Therapy in Hand Osteoarthritis
Keywords
Abstract
Dates
Last Verified: | 03/31/2019 |
First Submitted: | 04/08/2019 |
Estimated Enrollment Submitted: | 04/08/2019 |
First Posted: | 04/10/2019 |
Last Update Submitted: | 04/09/2019 |
Last Update Posted: | 04/11/2019 |
Actual Study Start Date: | 08/31/2018 |
Estimated Primary Completion Date: | 12/31/2018 |
Estimated Study Completion Date: | 01/31/2019 |
Condition or disease
Intervention/treatment
Drug: Glucosamine Sulfate
Phase
Arm Groups
Arm | Intervention/treatment |
---|---|
Glucosamine Sulfate Group (GS Group) GS Group is treated for at least 6 consecutive months with a single daily dose of 1500 mg of crystalline GS (powder sachets), in addition to conventional therapy. | |
Control Group Control Group receive only usual care therapy. The conventional therapy includes exercise for HOA and treatment with acetaminophen or oral NSAIDs or COX-2 inhibitors (150 mg Diclofenac tablets, 20 mg Piroxicam tablets, 550 mg Naproxen tablets, 200 mg Aceclofenac, 600 mg Ibuprofen tablets, 200 mg Celecoxib tablets, 60 mg Etoricoxib tablets). |
Eligibility Criteria
Ages Eligible for Study | 45 Years To 45 Years |
Sexes Eligible for Study | All |
Sampling method | Probability Sample |
Accepts Healthy Volunteers | Yes |
Criteria | Inclusion Criteria: - Mono or bilateral primary HOA and concomitant knee OA, according to the American College of Rheumatology (ACR) criteria - Treatment for at least 6 consecutive months with crystalline GS at the daily dose of 1500 mg in addition to the conventional therapy or with usual care alone. - HOA symptoms duration for at least 3 months defined as global hand pain score superior to 40 mm on a 0-100 VAS and a FIHOA score of at least 6. - Radiographic evidence of HOA within the previous 6 months with a radiological score of II-III (using the Kellgren method). Exclusion Criteria: - Erosive Osteoarthritis of the hand - Medical history of any inflammatory joint disease, septic arthritis, previous articular fracture of the concerned joints, monarticular post-traumatic OA of the finger, a history or the presence of any other rheumatic diseases that could cause secondary OA, such as hemochromatosis. - Ongoing therapy with opioid analgesics and any kind of topical treatment - Therapy with SYSADOAs other than GS, steroids by any route of administration and intra-articular injection of any joint with hyaluronic acid during the previous 6 months. - Contraindications or special warnings for GS presented in the data sheet. |
Outcome
Primary Outcome Measures
1. Difference between the two groups in the change of the patient's assessment of global hand pain on a 0- 100 mm Visual Analogue Scale [Basal time; one month; three months; six months]
Secondary Outcome Measures
1. Difference between the two groups in the change of the Functional Index for Hand Osteoarthritis (FIHOA) score [Basal time; one month; three months; six months]
2. Health Assessment Questionnaire (HAQ) [Basal time; one month; three months; six months]
3. Medical Outcomes Study 36-Item Short Form (SF-36) [Basal time; one month; three months; six months]
4. NSAIDs and/or acetaminophen consumption [Basal time; one month; three months; six months]